🍂 Enjoy the Fall Season! 🍂
MindTheDesk

Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

General Montana Archived • November 8, 2026 •
SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of treatment with 150 mg Q2W/450 mg Q4WSINTBILO® (tafolecimab injection) monotherapy significantly decreased non-HDL-C, vLDL-C, ApoB, and Lp(a) after 12-week treatment,…
Source: Missoulian MT | https://missoulian.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"What you put in is not always what you get out."
"Camping the Easyway"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Output is a realization of Input."